CytotherapyJul 21, 2026

Non-viral gene editing with platinum TALEN helps produce large amounts of cancer-targeting T cells

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 23, 2026

Abstract

Platinum transcription activator-like effector nuclease (TALEN) may offer higher editing efficiency than conventional TALENs.

Target-genome editing is becoming a promising tool for developing cellular products.
CRISPR-Cas9 is widely used for therapeutic genome editing but faces challenges like off-target effects and high patent costs.
Modified TALENs with non-repeat-variable di-residue variations could enhance editing efficiency compared to standard TALENs.

Simplified

Recently, target-genome editing has emerged as a next-generation tool for the clinical development of designed cellular products. Although Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 (CRISPR-Cas9) is the most frequently adopted nuclease for therapeutic genome editing, its widespread use is still hampered by potential off-target effects and high patent royalties. Platinum transcription activator-like effector nuclease (TALEN) is a modified TALEN that harbors non-repeat-variable di-residue (non-RVD) variations and confers higher efficiency than conventional TALENs lacking non-RVD variations.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

27%of authors

3 of 11

authors report competing interests

PubMed

Non-viral gene editing with platinum TALEN helps produce large amounts of cancer-targeting T cells

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief